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The purpose of this study was to examine the regulation of prosurvival factors heat shock factor 1 (HSF1) and breast cancer
susceptibility gene 1 (BRCA1) by a natural withanolide withaferin A (WA) in triple negative breast cancer cell lines MDA-MB-
231 and BT20. Western analysis was used to examine alternations in HSF1 and BRCA1 protein levels following WA treatment. A
protein synthesis inhibitor cycloheximide and a proteasome inhibitor MG132 were used to investigate the mechanisms of HSF1
and BRCA1 regulation by WA. It was found that WA induced a dose-dependent decrease in HSF1 and BRCA1 protein levels.
Further analysis showed that levels of HSF1 and BRCA1 proteins decreased rapidly after WA treatment, and this was attributed to
WA-induced denaturation of HSF1 and BRCA1 proteins and subsequent degradation via proteasome-dependent, and protein-
synthesis dependent mechanism. In summary, WA induces denaturation and proteasomal degradation of HSF1 and BRCA1
proteins. Further studies are warranted to examine the contribution of HSF1 and BRCA1 depletion to the anticancer effects of
WA in breast cancer.
1. Introduction
Withaferin A (WA) is a steroidal lactone naturally occurring
in the medicinal plant Withania somnifera, which has
recently been found to have potent anticancer and radio-
sensitizing effects in human cancer cell lines and in animal
cancer models without any noticeable systemic toxicity [1].
For breast cancer, WA has been found to induce cell cycle
arrest and apoptosis in vitro and inhibit tumor growth
in mouse models with xenograft of human breast cancer
cells [2, 3]. The mechanism of action for WA is currently
under extensive investigation. A number of targets have been
identified, including nuclear factor-κB [4], Notch [5], Hsp90
[6], STAT3 [7], and vimentin [8].
We hypothesized that WA may target breast cancer
susceptibility gene-1 (BRCA1) and heat shock factor 1
(HSF1) in breast cancer cells. BRCA1 plays a critical role in
DNA double-strand break repair. Although BRCA1 mutation
is linked to increased risk of breast cancer [9] and non-
physiological overexpression of BRCA1 induces apoptosis
[10], recent research showed that reduced BRCA1 expression
resulted in decreased viability of MDA-MB-231 cells [11],
suggesting functional BRCA1 as a therapeutic target. It has
also been reported that turnover of BRCA1 is involved
in radiation-induced apoptosis [12]. About 89% of triple-
negative breast cancers (defined by deficiency of estrogen-
receptor, progesterone receptor, and HER-2 receptor) have
wild-type BRCA1 [13], as such, BRCA1 may serve as a
therapeutic target for most cases of this difficult breast
cancer subtype. Another potential target is Heat shock factor
1 (HSF1), which is a transcription factor that stimulates
synthesis of heat shock proteins and thus a promising
target for cancer therapy. HSF1 has recently been shown
as a facilitator of transformation in breast cancer [14, 15].
Inhibition of HSF1 suppresses the progression of a wide
spectrum of cancers [16, 17].
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In the present study, we intended to examine the effects
of WA on BRCA1 and HSF1 protein expression in MDA-MB-
231 and BT20 triple-negative breast cancer cells as potential
mechanisms of its anticancer action. MDA-MB-231 and
BT20 cells are both triple-negative human breast cancer cell
lines with functional BRCA1. MDA-MB-231 cells are basal B
adenocarcinoma, and BT20 cells are basal A invasive ductal
carcinoma.
2. Materials and Methods
2.1. Cell Lines and Reagents. Triple negative MDA-MB-231
and BT20 human breast cancer cell lines were purchased
from the American Type Culture Collection (ATCC; Man-
assas, VA) and cultured in DMEM containing 5% fetal
bovine serum (FBS), 100 units/Ml penicillin, 100 μg/mL
streptomycin, and 2 mM glutamine. WA was purchased
from ChromaDex (Irvine, CA). The antibody against HSF1
was purchased from Cell Signaling Technology (Danvers,
MA) and the antibody against BRCA1 was purchased from
EMD4Biosciences (Darmstadt, Germany). The anti-β-actin
antibody was purchased from Millipore (Billerica, MA). The
anti-Annexin V-FITC-conjugated and propidium iodide (PI)
were purchased from BD Bioscience (Rockville, MD).
2.2. Annexin V-FITC/PI Flow Cytometry. The apoptotic
effects of WA were examined using Annexin V-FITC/PI flow
cytometry as previously described [18]. Briefly, MDA-MB-
231 or BT20 cells were treated with increasing doses of WA
for 24 h. Detached and adherent cells were then collected
and labeled for 15 min at room temperature with annexin
V- FITC (1 μg/mL) and with PI (40 μg/mL) and immediately
analyzed on a BD LSRII flow cytometer (BD Biosciences)
using BD FACSDiva6.0 software.
2.3. Western Analysis. Total proteins were extracted using
radioimmuno-precipitation assay buffer (20 mM Tris (pH
7.5), 150 mM NaCl, 1% IGEPAL CA-630, 0.5% sodium
deoxycholate, 1 mM ethylenediaminetetra-acetic acid, and
0.1% SDS) containing a protease/phosphatase inhibitor
cocktail (0.1 mg/mL PMSF, 30 μL/mL of aprotinin, 5 μg/mL
of leupeptin, and 1 mM sodium orthovanadate; Sigma).
Protein concentrations were determined using the BCA
protein assay reagent kit (Pierce, Rockford, IL). Equal
amount of proteins were subjected to SDS-polyacrylamide
gel electrophoresis (PAGE) and electroblotted onto nitro-
cellulose membranes (Hybond; Amersham, Piscataway, NJ).
After blocking with 3% nonfat dry milk in PBS for 1 h at
room temperature, blots were incubated with appropriate
primary antibodies overnight at 4◦C. Blots were then washed
and incubated with appropriate horseradish peroxidase
(HRP)-conjugated secondary antibodies for 1 h, and proteins
of interests were detected using a chemiluminescence kit
(Thermo Scientific, Rockford, IL). Next, blots were stripped
and reprobed for β-actin. The expression level of each
protein was normalized to the level of β-actin.
To examine whether WA modulates HSF1 and BRCA1
protein stability, MDA-MB-231 cells were treated with
100 μg/mL of protein synthesis inhibitor cycloheximide
(CHX) in the absence or presence of 2.5 μM WA for 6 or
24 h. Cells were then collected and proteins in triton-soluble
or triton-insoluble fractions were isolated as described
previously [19], and subjected to Western analysis for HSF1,
BRCA1 and β-actin.
To examine whether downregulation of HSF1 and
BRCA1 protein levels was attributed to proteasome-
dependent protein degradation, MDA-MB-231 cells were
pretreated with 30 μM of proteasome inhibitor MG132 for
1 h before treatment with 2.5 μM WA for 6 h. Cells were then
collected and proteins in triton-soluble or triton-insoluble
fractions were isolated and subjected to Western analysis.
2.4. Statistical Analysis. All data were analyzed using SPSS
Version 17.0 software (SPSS, Inc.). ANOVA was used for
comparison across treatment regimes. When an F test
indicated statistical significance, post hoc analysis was made
using the Tukey’s honestly significant difference procedure.
Significance was set at P < 0.05 for all comparisons.
3. Results
3.1. BT20 Cells Are More Sensitive to the Apoptotic Effect of
WA than MDA-MB-231 Cells. Although the apoptotic effect
of WA in MDA-MB-231 cells has been reported before,
its effects in other triple-negative cell lines are not known.
Considering the heterogeneous nature of the triple-negative
breast cancer subtype, we decided to include both MDA-MB-
231 and BT20 cells in this study. We first conducted Annexin
V-FITC/PI flow cytometry to examine the apoptotic effects of
WA. 2.5 μM of WA induced significant increase in apoptosis
in MDA-MB-231 cells at 24 h (Figure 1(a)). In BT20 cells,
1 μM of WA induced a significant increase in apoptosis at
24 h (Figure 1(b)), indicating higher sensitivity of BT20 to
the apoptotic effects of WA.
The induction of apoptosis by WA in MDA-MB-231
and BT20 cells at 24 h was accompanied by increased poly
(ADP-ribose) polymerase (PARP) cleavage and caspase-3
activation, as shown by Western analysis (Figure 1(c)).
3.2. WA Markedly Downregulates HSF1 and BRCA1 Proteins
in MDA-MB-231 and BT20 Cells. The regulation of two
prosurvival proteins HSF1 and BRCA1 in MDA-MB-231 and
BT20 cells by WA was examined using Western analysis. Both
HSF1 and BRCA1 proteins were found to be markedly down-
regulated by WA in a dose-dependent manner (Figure 2).
In MDA-MB-231 cells, HSF1 and BRCA1 protein levels
diminished after 2.5 μM WA treatment for 24 h. In BT20
cells, these two proteins diminished after 1 μM WA treatment
for 24 h.
3.3. Downregulation of HSF1 and BRCA1 is Predominantly
due to Decreased Protein Stability. To examine the time
course of WA-induced downregulation of HSF1 and BRCA1,
MDA-MB-231 cells were treated with vehicle (0.125%
DMSO) or 2.5 μM WA for 0, 1, 3, 6, 12, and 24 h. Western
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Figure 1: A and B: Effects of WA on MDA-MB-231 (a) and BT20 (b) cell apoptosis as measured by Annexin V-FITC-propidium iodide
flow cytometry. Cells were treated with indicated concentrations of WA for 24 h. Results were presented as mean (n = 3) SD. ∗, P < 0.05,
significantly different from control by one-way ANOVA. (C) Western analysis of the expression of PARP and caspase-3 in MDA-MB-231 and
BT20 cells. Cells were treated with indicated concentrations of WA for 24 h. Western for β-actin was conducted to confirm equal loading of
proteins.
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Figure 2: A. Western analysis of the expression of HSF1 and BRCA1
proteins in MDA-MB-231 and BT20 cells. Cells were treated with
indicated concentrations of WA for 24 h.
and BRCA1 proteins were rapidly decreased following WA
treatment. HSF1 protein levels were decreased at as early as
1 h post treatment, and BRCA1 protein levels were decreased
starting at 3 h post treatment (Figure 3), as compared to
vehicle groups. We also noticed that BRCA1 protein levels
in vehicle groups vary across the time points, with its levels
at 12 h and 24 h much lower than those at 3 h and 6 h after
treatment.
We then used a protein synthesis inhibitor CHX to
examine if WA is able to decrease HSF1 and BRCA1
protein stability. MDA-MB-231 cells were treated with CHX
alone or in combination with 2.5 μM WA for 6 or 24 h.
We found that co-treatment with CHX + WA markedly
decreased the protein levels of HSF1 and BRCA1 at both
6 h and 24 h, as compared to CHX alone in Triton-soluble
fractions, suggesting that WA may downregulate HSF1 and
BRCA1 protein levels posttranslationally by decreasing their
stability (Figure 4). As expected, WA treatment alone caused
a decrease in HSF1 and BRCA1 protein levels in Triton-
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Figure 3: Western analysis of the time course the effects of WA on
HSF1 and BRCA1 proteins levels in MDA-MB-231 cells. Cells were
treated with 0.125% DMSO or 2.5 μM WA for 0, 1, 3, 6, or 24 h.
fractions were increased by WA. Co-treatment with CHX
partially blocked WA-induced decrease in levels of HSF1 and
BRCA1 proteins in Triton-soluble fractions.
3.4. WA Induces Proteasome-Dependent Degradation of HSF1
and BRCA1 Proteins. To examine if downregulation of
HSF1 and BRCA1 protein levels by WA is mediated by
proteasomal protein degradation, MDA-MB-231 cells were
pretreated with 30 μM of a proteasome inhibitor MG132 for
1 h before treatment with 2.5 μM WA for 6 h (Figure 5). WA
alone decreased the protein levels of HSF1 and BRCA1 in
Triton-soluble fractions and increased their levels in Triton-
insoluble fractions. Pretreatment with MG132 before WA
further increased the levels of HSF1 and BRCA1 proteins
in Triton-insoluble fractions as compared to either MG132
or WA alone, suggesting that WA induced denaturation and
proteasome-dependent degradation of HSF1 and BRCA1
proteins.
We also observed that MG132 caused a decrease in
HSF1 and BRCA1 protein levels in Triton-soluble fractions
while increasing its levels in Triton-insoluble fractions, as
compared to controls.
4. Discussion
In the present study, we demonstrated that (1) the natural
withanolide WA has proapoptotic effects in both MDA-MB-
231 (basal B, adenocarcinoma) and BT20 (basal A, invasive
ductal carcinoma) triple-negative breast cancer cells, with
BT20 cells showing higher sensitivity; (2) the apoptotic
effects of WA are associated with diminished levels of HSF1
and BRCA1 proteins; (3) rapid downregulation of HSF1
and BRCA1 proteins by WA is predominantly attributed to
post-translational modulation via protein denaturation and
proteasomal degradation; (4) WA-induced down-regulation
of HSF1 and BRCA1 proteins is protein-synthesis dependent.
We found that downregulation of HSF1 and BRCA1 pro-
teins occurred rapidly following WA treatment, suggesting
potential decrease in protein stability. This was confirmed by
co-treatment with a protein synthesis inhibitor CHX along
with WA, as HSF1 and BRCA1 levels were much lower in
CHX + WA group as compared to CHX treatment alone in
Triton-soluble fractions. It is worth mentioning that WA-
induced downregulation of HSF1 and BRCA1 in Triton-
soluble fractions was partially/temporarily blocked by CHX,
suggesting that de novo protein synthesis is needed in this
process. One possible explanation is that certain labile or
short-lived proteins are involved in WA-induced degradation
of HSF1 and BRCA1 proteins.
Experiments using a proteasome inhibitor MG132
demonstrated that WA caused HSF1 and BRCA1 protein
denaturation and proteasome-dependent degradation, as
levels of these proteins in Triton-insoluble fractions were
much higher in MG132 + WA group as compared to either
MG132 or WA alone. The involvement of the ubiquitin-
proteasome pathway also suggests that inhibition of WA-
induced HSF1 and BRCA1 protein downregulation by CHX
could be due to CHX-induced depletion of short-lived E3
ubiquitin ligases, which warrants further investigation.
It is intriguing that MG132 alone induced a decrease
in both HSF1 and BRCA1 protein levels in Triton-soluble
fractions while inducing an increase in their levels in Triton-
insoluble fractions of breast cancer cell protein extract.
We speculate that this alteration may result from MG132-
induced accumulation of HSF1 and BRCA1 into nuclear
granules, rendering it insoluble. It has been reported that
proteasome inhibition by MG132 or lactacystin could cause
conformational changes of HSF1 molecules and trigger their
accumulation into nuclear granules [20]. Although it is not
known whether MG132 can cause similar subnuclear com-
partmentation of BRCA1 protein, Motoaki Sano demon-
strated that MG132 treatment induced translocation of
subnuclear compartment shift of another transcription fac-
tor peroxisome proliferator-activated receptor coactivator-1
(PGC-1) rendering it insoluble [21].
Additionally, we noticed that BRCA1 protein levels in
vehicle groups vary across the time points, with its levels at
12 h and 24 h much lower than those at 3 h and 6 h after
treatment. Earlier research has demonstrated that levels of
BRCA1 protein expression fluctuate during cell cycle [22].
BRCA1 has been shown to interact with both DNA and
cellular proteins [23]. The regulation of BRCA1 protein
expression is likely complicated.
As mentioned earlier, BRCA1 has been found to be
critically involved in cell survival in MDA-MB-231 cells [11].
BRCA1 also protects cancer cells against oxidative stress
by regulating antioxidant responses [24]. HSF1, a stress
response protein and an activator of heat-shock protein
encoding genes, is implicated in breast cancer initiation
and progression [25]. Increased HSF1 is associated with
reduced breast cancer survival [26]. The fact that attenuated
expression of HSF1 and BRCA1 proteins were associated
with the apoptotic effects of WA in both MDA-MB-231 and
BT20 cells suggests that they may play a role in the anticancer
action of WA in triple negative breast cancer cell lines. Cells
may not respond to DNA damage caused by WA when
these prosurvival factors are diminished, and thus enter
programmed cell death. However, directly confirming their
roles in the proapoptotic effect of WA could be challenging.
Because apoptotic concentrations of WA almost completely






































Figure 4: Effects of protein synthesis inhibitor CHX (100 μg/mL) alone or in combination with WA (2.5 μM) on HSF1 and BRCA1 protein





























Figure 5: Western analysis of the effects of a proteasome inhibitor MG132 (30 μM) alone or in combination with WA (2.5 μM) on HSF1 and
BRCA1 protein expression in Triton-soluble and Triton-insoluble fractions of MDA-MB-231 cell lyses at 6 h post WA treatment.
by protein denaturation, overexpression of BRCA1 or HSF1
protein may not be feasible.
In summary, we report here that WA causes denatura-
tion and proteasome-dependent degradation of HSF1 and
BRCA1 proteins in MDA-MB-231 and BT20 triple-negative
breast cancer cells. Further studies are needed to examine the
contribution of HSF1 and BRCA1 depletion to the anticancer
effects of WA in breast cancer.
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